MARKET

HSDT

HSDT

Helius Med Technologies Inc
NASDAQ
5.83
+0.23
+4.11%
After Hours: 5.84 +0.01 +0.17% 19:43 03/28 EDT
OPEN
5.62
PREV CLOSE
5.60
HIGH
5.90
LOW
5.58
VOLUME
10.70K
TURNOVER
0
52 WEEK HIGH
14.44
52 WEEK LOW
4.290
MARKET CAP
4.13M
P/E (TTM)
-0.4120
1D
5D
1M
3M
1Y
5Y
HSDT Stock Earnings: Helius Medical Tech Beats EPS, Misses Revenue for Q4 2023
Helius Medical Tech reported earnings per share of -$1.47 for the fourth quarter of 2023. The company reported revenue of $134,000. This was 46.40% worse than the analyst estimate for revenue in the same period. Helius medical tech reported results for the quarter.
Investorplace · 9h ago
Helius Medical Technologies Inc reports results for the quarter ended in December - Earnings Summary
Helius Medical Technologies Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of $1.47 per share. Revenue fell 52.5% to $134.00 million from the same quarter last year. The mean expectation of three analysts was for the company to lose $3.77 a share.
Reuters · 13h ago
Helius Medical Tech Q4 2023 GAAP EPS $(1.47) Beats $(3.77) Estimate, Sales $134.000K Miss $246.333K Estimate
Helius Medical Tech reported quarterly losses of $1.47 per share. The company reported quarterly sales of $134.000 thousand which missed the analyst consensus estimate of $246.333 thousand by 45.60%. The company also reported a 52.48 percent decrease in sales for the same period.
Benzinga · 14h ago
Recap: Helius Medical Tech Q4 Earnings
Helius Medical Tech reported its Q4 earnings on March 28. The company beat estimates by 61.0%. Revenue was down $148 thousand from the same period last year. Last quarter the company beat on EPS by $0.51 and the share price dropped 3.0% the next day.
Benzinga · 14h ago
*Helius Medical Tech 4Q Rev $134,000 >HSDT
Dow Jones · 14h ago
*Helius Medical Tech 4Q Loss/Shr $1.47 >HSDT
Dow Jones · 14h ago
Helius Medical Technologies GAAP EPS of -$1.47 beats by $2.30, revenue of $0.13M misses by $0.12M
Helius Medical Technologies Q4 GAAP EPS of -$1.47 beats by $2.30, revenue of $0.13M misses by $ 0.12M. The company's Q4 revenue was down 53.6% from the same period last year.
Seeking Alpha · 14h ago
After-Hours Earnings Report for March 28, 2024 : ACHV, ACNT, AREC, AXDX, CPTN, CURV, DARE, DNMR, DYAI, FORA, HSDT, INLX
NASDAQ · 16h ago
More
About HSDT
Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.

Webull offers Helius Medical Technologies Inc stock information, including NASDAQ: HSDT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HSDT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HSDT stock methods without spending real money on the virtual paper trading platform.